RMD•benzinga•
ResMed Earnings Perspective: Return On Invested Capital
Summary
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga